Chinese biotech CEOs say US tensions won’t curb booming licensing deals
Chinese biotech CEOs say they are not worried about rising US political tension and regulatory scrutiny.
US lawmakers have increased scrutiny, referencing the America First Investment Policy and the COINS Act aimed at limiting Chinese biotech licensing.
Market data shows licensing activity continues to grow, with Chinese assets expected to account for more than two thirds of total licensing deal value this year, up from about half in 2025.
In the first half of 2026, 81 out licensing deals from Chinese firms to foreign buyers were valued at $110 billion, representing 80 percent of the full year total for 2025, indicating the market is not being deterred.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “‘Money has spoken’: Why Chinese biotech CEOs tell Fierce they’re unfazed about rising US tensions”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that